Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

🇺🇸 Seeking Alpha (US) —

AI Summary

The article highlights Arbutus Biopharma's $230 million share buyback and cash payments from Moderna as factors that may reduce financial risk. It frames these resources as supporting the company's prospects for developing a potential hepatitis B cure.

Markets Health Arbutus Biopharma share buyback Moderna hepatitis B drug development biopharmaceuticals

Read original source →